# Multimodal Profiling Reveals Distinct Endothelial Activation Pathways Regulated by Flow and Heparan Sulfate

**Authors:** Ian C. Harding, Nicholas R. O’Hare, Ira M. Herman, Eno E. Ebong

PMC · DOI: 10.1007/s12195-026-00884-3 · 2026-02-01

## TL;DR

This study shows that heparan sulfate in the endothelial glycocalyx helps prevent inflammation in blood vessels under normal flow conditions, but not reactive oxygen species production.

## Contribution

The study reveals that heparan sulfate specifically suppresses flow-dependent endothelial inflammation but not oxidative stress.

## Key findings

- Intact heparan sulfate suppresses pro-inflammatory gene expression under normal flow conditions.
- HS degradation leads to an inflammatory endothelial phenotype similar to stagnant flow conditions.
- ROS production remains unaffected by HS degradation under normal flow.

## Abstract

Atherosclerotic cardiovascular disease originates from endothelial dysfunction, characterized by a shift toward a pro-inflammatory state and increased production of reactive oxygen species (ROS). This dysfunction occurs under adverse mechanical conditions, such as blood flow oscillation, multi-directionality, recirculation, shear stress gradients, and low or stagnation flows. This study investigates how degradation of heparan sulfate (HS), a major component of the endothelial glycocalyx, drives the transition of endothelial cells from a functional, anti-inflammatory, and antioxidant phenotype under streamlined flow conditions to a dysfunctional, pro-inflammatory, and pro-oxidant phenotype when flow is stagnant. Pro-inflammatory and pro-oxidant endothelial behavior precedes atherosclerosis development.

Human aortic endothelial cells were exposed to uniform shear stress (14 dynes/cm2) to model healthy endothelium. Unhealthy conditions were simulated via static conditions (0 dynes/cm2) or enzymatic HS degradation using heparinase III. Endothelial cell phenotype was assessed using fluorescent labeling, confocal microscopy, Western blotting, and RNA sequencing.

Endothelial cells conditioned by 14 dynes/cm2 shear stress without heparinase III exhibited low expression of pro-inflammatory genes (HIF1A, VCAM1, and IL1B), minimal ROS production, and up-regulation of Kruppel-like transcription factors. Under the same flow conditions, HS degradation via heparinase III induced an inflammatory phenotype, resembling responses observed at 0 dynes/cm2 shear stress, while ROS levels remained largely unaffected.

The endothelial glycocalyx is a protective, dynamic, and complex structure, with HS as a key component. This study demonstrates that intact HS mitigates endothelial dysfunction by suppressing inflammation linked to flow-dependent atherosclerosis, but not ROS production. Future research will focus on translating these findings into HS-targeted therapies for atherosclerotic cardiovascular disease.

The online version contains supplementary material available at 10.1007/s12195-026-00884-3.

## Linked entities

- **Genes:** HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412], IL1B (interleukin 1 beta) [NCBI Gene 3553]
- **Chemicals:** heparan sulfate (PubChem CID 137699201)
- **Diseases:** atherosclerotic cardiovascular disease (MONDO:1060134), atherosclerosis (MONDO:0005311)

## Full-text entities

- **Genes:** VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}
- **Diseases:** Atherosclerotic cardiovascular disease (MESH:D050197), endothelial dysfunction (MESH:D014652), inflammation (MESH:D007249)
- **Chemicals:** HS (MESH:D006497), ROS (MESH:D017382)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13031597/full.md

---
Source: https://tomesphere.com/paper/PMC13031597